Use of the [35S]GTPγS Binding Assay to Determine Ligand Efficacy at G Protein-Coupled Receptors

G Protein-Coupled Receptors: Essential Methods

Volumn , Issue , 2010, Pages 53-68

  Kara, Elodie ^a   Strange, Philip G ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

35S GTP S binding assay determining ligand efficacy at G protein coupled receptors; 35S GTP S binding assay under conditions for GPCRs coupled to Gi o proteins; BSA in assays for preventing ligand loss; Chinese hamster ovary (CHO) cells expressing recombinant GPCR; In vitro systems to measure agonist efficacy; Methods for assessing efficacy for agonists for G protein coupled receptors (GPCRs); Other assays for efficacy at GPCRs; Protocol 3.2 determination of concentration of GDP in 35S GTP S binding assay; Protocol 3.3 data analysis of GDP requirements; Understanding and quantifying drug efficacy

Indexed keywords

EID: 84886326028     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470749210.ch3     Document Type: Chapter

References (30)

1. Ohlsen, R.I. and Pilowsky, L.S. (2005) The place of partial agonism in psychiatry: recent developments. J. Psychopharmacol., 19, 408-413.
2. Hoffmann, C., Gaietta, G., Bunemann, M. et al. (2005) A FlAsH-based FRET approach to determine G protein-coupled receptor activation in living cells. Nat. Methods, 2, 171-176.
3. 2(long) dopamine receptors: ligand binding and functional assays. Br. J. Pharmacol., 124, 978-984.
4. 2(short) dopamine receptors determined in ligand binding and functional assays. J. Neurochem., 69, 2589-2598.
5. Black, J.W. and Leff, P. (1983) Operational models of pharmacological agonism. Proc. R. Soc. Lond. B Biol. Sci., 220, 141-162.
6. Trzeciakowski, J.P. (1999) Stimulus amplification, efficacy, and the operational model. Part I- binary complex occupancy mechanisms. J. Theor. Biol., 198, 329-346.
7. Strange, P.G. (2007) Mechanisms underlying agonist efficacy. Biochem. Soc. Trans., 35, 733-736. A review on the importance of considering different parameters in efficacy assessment.
8. 35S]GTPγ S binding assay: approaches and applications in pharmacology. Life Sci., 74, 489-508. An overview on the GTPγ S binding technique.
9. Birnbaumer, L., Abramowitz, J. and Brown, A.M. (1990) Receptor-effector coupling by G proteins. Biochim. Biophys. Acta, 1031, 163-224.
10. Labrecque, J., Anastassov, V., Lau, G. et al. (2005) The development of an europium-GTP assay to quantitate chemokine antagonist interactions for CXCR4 and CCR5. Assay Drug Dev. Technol., 3, 637-648.
11. Lowry, O., Rosebrough, N., Farr, A. and Randall, R. (1951) Protein measurement with the folin phenol reagent. J. Biol. Chem., 193, 265-275.
12. 2long dopamine receptors expressed in recombinant cells. Br. J. Pharmacol., 118, 1544-1550.
13. 2(short) dopamine receptor. J. Neurochem., 82, 1106-1117.
14. 35S]GTPγ S binding assays. Trends Pharmacol. Sci., 24, 87-90.
15. Asano, T., Pedersen, S.E., Scott, C.W. and Ross, E.M. (1984) Reconstitution of catecholamine-stimulated binding of guanosine 5'-O-(3-thiotriphosphate) to the stimulatory GTP-binding protein of adenylate cyclase. Biochemistry, 23, 5460-5467.
16. 35S]GTPγ S binding. Methods Mol. Biol., 237, 135-143.
17. Selley, D.E., Sim, L.J., Xiao, R. et al. (1997) μ-Opioid receptor-stimulated guanosine-5'-O-(μ-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy. Mol. Pharmacol., 51, 87-96.
18. 35S]GTPγ S binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. J. Biol. Chem., 273, 16865-16873.
19. Lazareno, S., Farries, T. and Birdsall, N.J. (1993) Pharmacological characterization of guanine nucleotide exchange reactions in membranes from CHO cells stably transfected with human muscarinic receptors m1-m4. Life Sci., 52, 449-456.
20. Mueller, A., Mahmoud, N.G., Goedecke, M.C. et al. (2002) Pharmacological characterization of the chemokine receptor, CCR5. Br. J. Pharmacol., 135, 1033-1043.
21. 2 dopamine receptors. Biochem. Pharmacol., 67, 1657-1665.
22. 2 dopamine receptor. Br. J. Pharmacol., 149, 291-299. This article shows the importance of assay conditions in assessing ligand efficacy.
23. 2 dopamine receptors. Br. J. Pharmacol., 145, 34-42.
24. 1A receptors. J. Neurochem., 74, 347-357.
25. Haworth, B., Lin, H., Fidock, M. et al. (2007) Allosteric effects of antagonists on signalling by the chemokine receptor CCR5. Biochem. Pharmacol., 74, 891-897.
26. 2 guanine nucleotide-binding protein-coupled receptor: utilization of receptor state binding affinities. Mol. Pharmacol., 42, 432-438.
27. 2 receptors: G protein activation and prolactin release. Eur. J. Pharmacol., 535, 135-144.
28. 2 dopamine receptor: evidence for persistent receptor/G protein interaction after agonist stimulation. Br. J. Pharmacol., 151, 144-152.
29. 2L cell line: evidence for induction of ligand-specific receptor states. Mol. Pharmacol., 66, 97-105.
30. Kenakin, T. (2005) New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat. Rev. Drug Discov., 4, 919-927.